WHAT IS CLAIMED IS:

1. A composition for the treatment of an ocular condition, wherein the composition is pharmaceutically acceptable and comprises pilocarpine hydrochloride at a concentration from 1.0 to 1.5% w/v, and wherein the ocular condition is selected from the group consisting of presbyopia, hyperopia, mydriasis, anisocoria, accommodative esotropia, myopia, and astigmatism.

2. The composition of any preceding claim, wherein the composition is applied once daily.

3. The composition of any preceding claim, wherein the composition is applied twice daily.

4. The composition of any preceding claim, wherein the ocular condition is presbyopia.

5. The composition of any preceding claim, wherein the ocular condition is hyperopia.

6. The composition of any preceding claim, wherein the composition comprises 1.25% w/v pilocarpine hydrochloride.

7. The composition of any preceding claim, wherein pilocarpine hydrochloride is the sole active ingredient.

8. The composition of any preceding claim, further comprising a preservative.

9. The composition of any preceding claim, wherein the composition comprises 1.25% w/v pilocarpine hydrochloride, boric acid, sodium citrate dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and water.

10. The composition of any preceding claim, wherein the composition comprises about 1.25% w/v pilocarpine hydrochloride, about 1.0% w/v boric acid, about 0.015% w/v sodium citrate dihydrate, about 0.08% w/v sodium chloride, and about 0.0075% w/v benzalkonium chloride.

11. The composition of any preceding claim, wherein the composition consists essentially of 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate

~~dihydrate, 0.08% w/v sodium chloride, and 0.0075% w/v benzalkonium chloride, with a pH of 5.0.~~

~~12. The composition of any preceding claim, wherein the composition reduces the incidence of at least one adverse event selected from the group consisting of ocular blurring, ocular discomfort, eye pain, brow ache, blurry vision, light sensitivity, ocular stinging, and ocular itching, compared to administration of a second ophthalmic composition comprising pilocarpine and a polymer, wherein the second composition comprises 1% w/v pilocarpine and the polymer is hydroxy propyl methyl cellulose.~~

~~13. A composition for improving at least one vision parameter, wherein the composition is pharmaceutically acceptable and comprises pilocarpine hydrochloride at a concentration from 1.0 to 1.5% w/v, and wherein the at least one vision parameter is selected from the group consisting of near vision acuity, distance vision acuity, night vision, day vision, glare, and light scattering.~~

~~14. The composition of claim 13, wherein the vision parameter is near vision acuity.~~

~~15. The composition of any one of claims 13-14, wherein the vision parameter is distance vision acuity.~~

~~16. The composition of any one of claims 13-15, wherein the composition comprises 1.25% w/v pilocarpine hydrochloride as the sole active ingredient.~~

~~17. The composition of any one of claims 13-16, wherein the composition comprises 1.25% w/v pilocarpine hydrochloride, boric acid, sodium citrate dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and water.~~

~~18. A composition for the improvement of near vision in a patient with presbyopia, the composition comprising 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, 0.0075% w/v benzalkonium chloride, and water, with a pH of 3.0-5.5.~~

~~**19.** A composition consisting essentially of 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, and 0.0075% w/v benzalkonium chloride, with a pH of 3.0-5.5.~~

1. Use of a composition in the manufacture of a medicament for treating presbyopia, wherein the composition is pharmaceutically acceptable and comprises pilocarpine hydrochloride at a concentration of 1.25% w/v, wherein pilocarpine hydrochloride is the sole active ingredient, and wherein the composition further comprises boric acid, sodium citrate dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and water.

2. The use of claim 1, wherein the composition is to be applied once daily or twice daily.

3. The use of any preceding claim, wherein the composition comprises 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, and 0.0075% w/v benzalkonium chloride.

4. The use of any preceding claim, wherein the composition does not comprise a polymer.

5. The use of any preceding claim, wherein the composition consists essentially of 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, and 0.0075% w/v benzalkonium chloride, with a pH of 5.0.

6. Use of a composition in the manufacture of a medicament for improving at least one vision parameter in a patient with presbyopia, wherein the composition is pharmaceutically acceptable, and wherein the composition comprises 1.25% w/v pilocarpine hydrochloride, boric acid, sodium citrate dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and water, and wherein the at least one vision parameter is selected from the group consisting of near vision acuity, distance vision acuity, night vision, day vision, glare, and light scattering, wherein pilocarpine hydrochloride is the sole active ingredient.

7. The use of claim 6, wherein the vision parameter is near vision acuity or is distance vision acuity.

8. The use of any one of claims 6-7, wherein the composition does not comprise a polymer.

9. Use of a composition in the manufacture of a medicament for improving near vision in a patient with presbyopia, the composition comprising 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, 0.0075% w/v benzalkonium chloride, and water, with a pH of 3.0-5.5, wherein pilocarpine hydrochloride is the sole active ingredient.

10. The use of claim 9, wherein the composition does not comprise a polymer.